The Isocitrate Dehydrogenase [NADP] Mitochondrial pipeline drugs market research report outlays comprehensive information on the Isocitrate Dehydrogenase [NADP] Mitochondrial targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Isocitrate Dehydrogenase [NADP] Mitochondrial pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Hematological Disorders, and Gastrointestinal which include the indications Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Cytopenia, and Liver Failure (Hepatic Insufficiency). It also reviews key players involved in Isocitrate Dehydrogenase [NADP] Mitochondrial targeted therapeutics development with respective active and dormant or discontinued products.
The Isocitrate Dehydrogenase [NADP] Mitochondrial pipeline targets constitutes close to ten molecules. Out of which, approximately ten molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 1, 1, 2, 1, 2, and 2 respectively.
Isocitrate Dehydrogenase [NADP] Mitochondrial overview
Isocitrate dehydrogenase [NADP], mitochondrial (IDH2) is an enzyme that catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate. This process synthesizes NADPH, which is essential for mitochondrial redox balance. IDH2 is located in the mitochondrial matrix. It acts in the forward Krebs cycle as an NADP+-consuming enzyme. IDH2 is encoded by the IDH2 gene in humans.
For a complete picture of Isocitrate Dehydrogenase [NADP] Mitochondrial’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
